Prostate cancer staging (F-18 PSMA PET-CT)
Diagnosis almost certain
Disclosures
- updated 14 May 2023:
Nothing to disclose
Updates to Case Attributes
Title
was changed:
Prostate cancer staging with F(F-18 PSMA PET-CT)
Age
changed from 60 to 60 years.
Presentation
was changed:
Prostate cancer high risk patient. Staging prior to radical treatment.
Body
was changed:
F-18 PSMA is useful in the staging of high risk prostate cancer patients being considered for radical therapy.
F-18 PSMA has been shown to have a higher diagnostic accuracy for primary staging compared with CT and bone scan (92% vs 65% respectively), a greater treatment impact (28% vs 15% respectively) and fewer uncertain results (7% vs 23% respectively).1.
-<p>F-18 PSMA is useful in the staging of high risk prostate cancer patients being considered for radical therapy. </p><p>F-18 PSMA has been shown to have a higher diagnostic accuracy for primary staging compared with CT and bone scan (92% vs 65% respectively), a greater treatment impact (28% vs 15% respectively) and fewer uncertain results (7% vs 23% respectively).<sup>1</sup></p>- +<p>F-18 PSMA is useful in the staging of high risk prostate cancer patients being considered for radical therapy. </p><p>F-18 PSMA has been shown to have a higher diagnostic accuracy for primary staging compared with CT and bone scan (92% vs 65% respectively), a greater treatment impact (28% vs 15% respectively) and fewer uncertain results (7% vs 23% respectively) <sup>1</sup>.</p>
References changed:
- 2. Foley RW, Redman SL, Graham RN, Loughborough WW, Little D. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. (2020) Clinical radiology. 75 (12): 903-913. <a href="https://doi.org/10.1016/j.crad.2020.06.031">doi:10.1016/j.crad.2020.06.031</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/32782128">Pubmed</a> <span class="ref_v4"></span>
- Foley RW, Redman SL, Graham RN, Loughborough WW, Little D. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. (2020) Clinical radiology. 75 (12): 903-913. <a href="https://doi.org/10.1016/j.crad.2020.06.031">doi:10.1016/j.crad.2020.06.031</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/32782128">Pubmed</a> <span class="ref_v4"></span>
Systems changed:
- Oncology
Updates to Study Attributes
Caption
was added:
F-18 PSMA PET-CT
Findings
was changed:
There is marked focal PSMA uptake in the right side of the prostate corresponding to the primary tumour. There is a 10mm10 mm mildly PSMA avid right pelvic sidewall lymph node which is likely involved. No nodal or metastatic disease elsewhere.
Updates to Link Attributes
Title
was removed:
Type
was removed.
Visible
changed from true to false.
Updates to Link Attributes
Title
was added:
Slug
was set to
prostate-cancer-staging-f-18-psma-pet-ct.
Type
was set to
.
Visible
was set to
false.
Content
was set to
82766.
Content Type
was set to
Case.
Updates to Primarylink Attributes
Title
was added:
Prostate cancer staging (F-18 PSMA PET-CT)
Slug
was set to
prostate-cancer-staging-f-18-psma-pet-ct-1.
Type
was set to
PrimaryLink.
Visible
was set to
true.
Content
was set to
82766.
Content Type
was set to
Case.